Holen Sie sich die Stockscreener-App
53.07
8.46%
4.14
Handel nachbörslich:
52.87
-0.20
-0.38%
Schlusskurs vom Vortag:
$48.93
Offen:
$49.74
24-Stunden-Volumen:
2.46M
Relative Volume:
1.29
Marktkapitalisierung:
$5.06B
Einnahmen:
$38.34M
Nettoeinkommen (Verlust:
$-488.30M
KGV:
-9.5106
EPS:
-5.5801
Netto-Cashflow:
$-303.14M
1W Leistung:
+8.88%
1M Leistung:
-5.54%
6M Leistung:
-7.43%
1J Leistung:
+22.03%
1-Tages-Spanne:
$49.62
$54.10
1-Wochen-Bereich:
$46.48
$54.10
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
53.07 | 4.66B | 38.34M | -488.30M | -303.14M | -5.5801 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Is CRISPR Therapeutics AG backed by strong institutional buyingJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - mfd.ru
Can CRISPR Therapeutics AG stock outperform in a bear marketQuarterly Market Summary & Proven Capital Preservation Tips - mfd.ru
CRISPR Therapeutics (CRSP) Stock: Why Bad Earnings Sparked a 9% Rally - CoinCentral
CRISPR Therapeutics: A Biotech Stock Poised for Growth - Intellectia AI
Why CRISPR Therapeutics stock is up today (despite its Q4 earnings miss) - MSN
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 - The Motley Fool
CRISPR Therapeutics Stock Rises Despite Poor Q4 Earnings - Intellectia AI
ARK Investment’s Strategic Purchase in CRISPR Therapeutics - StocksToTrade
Why Is CRISPR Therapeutics Stock Surging Friday?CRISPR Therapeutics (NASDAQ:CRSP) - Benzinga
CRSP: TD Cowen Raises Price Target Following Hold Rating | CRSP Stock News - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 8% on Analyst Upgrade - MarketBeat
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - TradingView
CRISPR Therapeutics: Casgevy Outperformance and Advancing In Vivo Pipeline Underpin Buy Rating - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $82.00 - MarketBeat
Needham Raises CRSP Price Target with a Buy Rating | CRSP Stock News - GuruFocus
CRISPR Therapeutics: Buy-Rated, Multi-Franchise Gene-Editing Platform with Strengthening CASGEVY Launch and Catalyst-Rich 2026 Outlook - TipRanks
Crispr Therapeutics (CRSP) Reports Lower-Than-Expected Q4 Revenue - GuruFocus
Decoding CRISPR Therapeutics AG (CRSP): A Strategic SWOT Insight - GuruFocus
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates - Bitget
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results - MarketBeat
Liquidity Mapping Around (CRSP) Price Events - Stock Traders Daily
Crispr Therapeutics earnings missed by $0.20, revenue fell short of estimates - Investing.com
CRISPR Therapeutics (CRSP) Q4 Earnings Miss Expectations - GuruFocus
CRISPR Therapeutics AG SEC 10-K Report - TradingView
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q4 Revenue $864,000 - marketscreener.com
CRISPR Therapeutics Earnings Report: Q4 Overview - Benzinga
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Is CRISPR Therapeutics AG showing insider buying2025 Volatility Report & Fast Gaining Stock Reports - mfd.ru
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 69.80% Potential Upside - DirectorsTalk Interviews
Guidance Update: Is CRISPR Therapeutics AG backed by strong institutional buyingGlobal Markets & Daily Chart Pattern Signals - baoquankhu1.vn
Aug PreEarnings: Is CRISPR Therapeutics AG backed by strong institutional buyingCEO Change & Capital Protection Trading Alerts - baoquankhu1.vn
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million - Yahoo Finance
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Top CRISPR Companies for 2026 and How to Invest - The Motley Fool
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics AG $CRSP Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline - Finviz
CRISPR Therapeutics AG (CRSP) Stock Analysis: Navigating The 64% Potential Upside - DirectorsTalk Interviews
CRISPR Therapeutics AG (CRSP) expected to beat earnings estimates: Should you buy? - MSN
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
CRISPR Therapeutics (CRSP) Price Target Increased by 14.61% to 82.91 - Nasdaq
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? - TradingView
Pathway Capital Management LP Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Tuesday - MarketBeat
Does CRISPR Therapeutics (CRSP) Pipeline Expansion And ARK’s Buying Redefine Its Long‑Term Narrative? - simplywall.st
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Layoff Watch: Will CRISPR Therapeutics AG benefit from government policyQuarterly Trade Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Why (CRSP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crispr Therapeutics Ag-Aktie (CRSP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Prasad Raju | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
45.15 |
34,972 |
1,578,986 |
41,739 |
| Prasad Raju | Chief Financial Officer |
Jan 22 '26 |
Sale |
60.19 |
34,972 |
2,104,965 |
6,767 |
| Kulkarni Samarth | Chief Executive Officer |
Jan 22 '26 |
Sale |
60.23 |
60,000 |
3,613,800 |
134,201 |
| Kulkarni Samarth | Chief Executive Officer |
Jan 20 '26 |
Sale |
51.75 |
30,000 |
1,552,498 |
194,201 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):